BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31524099)

  • 1. Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
    Kostić M; Milosavljević MN; Stefanović S; Ranković G; Janković SM
    J Chemother; 2020 Feb; 32(1):21-29. PubMed ID: 31524099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Benefit Analysis of Tafenoquine for Radical Cure of
    Suh J; Kim JH; Kim JD; Kim C; Choi JY; Lee J; Yeom JS
    J Korean Med Sci; 2022 Jul; 37(27):e212. PubMed ID: 35818703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
    Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
    PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
    Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
    Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    Warrasak S; Euswas A; Fukuda MM; Ittiverakul M; Miller RS; Krudsood S; Ohrt C
    Int Ophthalmol; 2019 Aug; 39(8):1767-1782. PubMed ID: 30269312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
    N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
    Anjum MU; Naveed AK; Mahmood SN; Naveed OK
    Travel Med Infect Dis; 2020; 36():101576. PubMed ID: 32036012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
    St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
    Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
    Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model.
    Price DJ; Nekkab N; Monteiro WM; Villela DAM; Simpson JA; Lacerda MVG; White MT; Devine A
    PLoS Med; 2024 Jan; 21(1):e1004255. PubMed ID: 38194420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primaquine treatment and relapse in Plasmodium vivax malaria.
    Rishikesh K; Saravu K
    Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
    Brito M; Rufatto R; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Menezes A; Ataídes R; Batista Pereira D; Lacerda M
    Lancet Glob Health; 2024 Mar; 12(3):e467-e477. PubMed ID: 38365417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
    N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    Rajapakse S; Rodrigo C; Fernando SD
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafenoquine for
    Sharma J; Gautam CS; Singh H; Singh J
    Indian J Med Res; 2021 Jun; 154(6):797-805. PubMed ID: 35662084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
    Kitchener S; Nasveld P; Edstein MD
    Am J Trop Med Hyg; 2007 Mar; 76(3):494-6. PubMed ID: 17360873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Sex-Stratified
    Devine A; Howes RE; Price DJ; Moore KA; Ley B; Simpson JA; Dittrich S; Price RN
    Am J Trop Med Hyg; 2020 Jul; 103(1):394-403. PubMed ID: 32372747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
    Edstein MD; Walsh DS; Eamsila C; Sasiprapha T; Nasveld PE; Kitchener S; Rieckmann KH
    Med Trop (Mars); 2001; 61(1):56-8. PubMed ID: 11584657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.